Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) – Drugs In Development, 2024 report and make more profitable business decisions.
Dravet syndrome, also known as severe myoclonic epilepsy of infancy, is a rare genetic disorder that causes a severe form of epilepsy. It usually starts in the first year of life with prolonged seizures triggered by fever or high temperature. Children with Dravet syndrome have various types of seizures that are difficult to treat with medications. They also have developmental delays, cognitive impairment, behavioral problems, and other neurological symptoms. Dravet syndrome is caused by mutations in the SCN1A gene, which affects the function of sodium channels in the brain. The diagnosis is based on clinical features and genetic testing. There is no cure for Dravet syndrome, but treatments aim to reduce the frequency and severity of seizures and improve the quality of life of patients and families.
The Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) drugs in development market research report provide comprehensive information on the therapeutics under development for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 42 molecules, with 40 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
a:head Bio AGAstrogen Ltd
Baergic Bio Inc
Bio-Pharm Solutions Co Ltd
BioNxt Solutions Inc.
Bloom Science Inc
Bright Minds Biosciences Inc
CAMP4 Therapeutics Corp
Celosia Therapeutics Pty Ltd
Eisai Co Ltd
Encoded Therapeutics Inc
EpyGenix Therapeutics Inc
First Medical Center of Chinese PLA General Hospital
Herophilus
IAMA Therapeutics Srl
Icahn School of Medicine at Mount Sinai
Jazz Pharmaceuticals Plc
JD Bioscience Inc
LifeSplice Pharma LLC
Longboard Pharmaceuticals Inc
Mediphage Bioceuticals Inc
NeuCyte Inc
Neuroene Therapeutics LLC
Otsuka Pharmaceutical Co Ltd
Regel Therapeutics Inc
Stoke Therapeutics Inc
StrideBio Inc
Sumitomo Pharma Co Ltd
Supernus Pharmaceuticals Inc
Takeda Pharmaceutical Co Ltd
Tevard Biosciences LLC
Theracule AS
Xenon Pharmaceuticals Inc
Xeris Biopharma Holdings Inc
Table of Contents
Table
Figures
Frequently asked questions